Hypertensive disorders in pregnancy are associated with increased risk of maternal, fetal, and neonatal morbidity and mortality. It is important to distinguish between pre-existing (chronic) hypertension and gestational hypertension, developing after 20 weeks of gestation and usually resolving within 6 weeks postpartum. There is a consensus that systolic blood pressure ≥ 170 or diastolic blood pressure ≥ 110 mmHg is an emergency and hospitalization is indicated. The selection of the antihypertensive drug and its route of administration depend on the expected time of delivery. The current European guidelines recommend initiating drug treatment in pregnant women with persistent elevation of blood pressure ≥ 150/95 mmHg and at values > 140/90 mmHg in women with gestational hypertension (with or without proteinuria), with pre-existing hypertension with the superimposition of gestational hypertension, and with hypertension with subclinical organ damage or symptoms at any time during pregnancy. Methyldopa, labetalol, and calcium antagonists (the most data are available for nifedipine) are the drugs of choice. The results of the CHIPS and CHAP studies are likely to reduce the threshold for initiating treatment. Women with a history of hypertensive disorders in pregnancy, particularly those with pre-eclampsia, are at high risk of developing cardiovascular disease later in life. Obstetric history should become a part of the cardiovascular risk assessment in women.

Center for Cardiovascular Prevention Charles University Prague 1st Faculty of Medicine and Thomayer University Hospital Prague Czech Republic

Department of Medicine 2 Charles University Prague 1st Faculty of Medicine Prague Czech Republic

Zobrazit více v PubMed

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165–3241. doi: 10.1093/eurheartj/ehy340. PubMed DOI

Shen M, Tan H, Zhou S, Smith GN, Walker MC, Wen SW. Trajectory of blood pressure change during pregnancy and the role of pre-gravid blood pressure: a functional data analysis approach. Sci Rep. 2017;7(1):6227. doi: 10.1038/s41598-017-06606-0. PubMed DOI PMC

Stergiou GS, Palatini P, Asmar R, Ioannidis JP, Kollias A, Lacy P, et al. Recommendations and Practical Guidance for performing and reporting validation studies according to the Universal Standard for the validation of blood pressure measuring devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) J Hypertens. 2019;37(3):459–466. doi: 10.1097/HJH.0000000000002039. PubMed DOI

Davis GK, Roberts LM, Mangos GJ, Brown MA. Comparisons of auscultatory hybrid and automated sphygmomanometers with mercury sphygmomanometry in hypertensive and normotensive pregnant women: parallel validation studies. J Hypertens. 2015;33(3):499–505. doi: 10.1097/HJH.0000000000000420. PubMed DOI

Mounier-Vehier C, Amar J, Boivin JM, Denolle T, Fauvel JP, Plu-Bureau G, et al. Hypertension and pregnancy: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology. Fundam Clin Pharmacol. 2017;31(1):83–103. doi: 10.1111/fcp.12254. PubMed DOI

van den Born BH, Lip GYH, Brguljan-Hitij J, Cremer A, Segura J, Morales E, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):37–46. doi: 10.1093/ehjcvp/pvy032. PubMed DOI

O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731–1768. doi: 10.1097/HJH.0b013e328363e964. PubMed DOI

Magee LA, Ramsay G, von Dadelszen P. What is the role of out-of-office BP measurement in hypertensive pregnancy? Hypertens Preg. 2008;27(2):95–101. doi: 10.1080/10641950801950197. PubMed DOI

Ditisheim A, Wuerzner G, Ponte B, Vial Y, Irion O, Burnier M, et al. Prevalence of hypertensive phenotypes after preeclampsia: a prospective cohort study. Hypertension. 2018;71(1):103–109. doi: 10.1161/HYPERTENSIONAHA.117.09799. PubMed DOI

Tucker KL, Mort S, Yu LM, Campbell H, Rivero-Arias O, Wilson HM, et al. Effect of self-monitoring of blood pressure on diagnosis of hypertension during higher-risk pregnancy: the BUMP 1 randomized clinical trial. JAMA. 2022;327(17):1656–1665. doi: 10.1001/jama.2022.4712. PubMed DOI PMC

Chappell LC, Tucker KL, Galal U, Yu LM, Campbell H, Rivero-Arias O, et al. Effect of self-monitoring of blood pressure on blood pressure control in pregnant individuals with chronic or gestational hypertension: the BUMP 2 Randomized Clinical Trial. JAMA. 2022;327(17):1666–1678. doi: 10.1001/jama.2022.4726. PubMed DOI PMC

Denolle T, Weber JL, Calvez C, Getin Y, Daniel JC, Lurton O, et al. Diagnosis of white coat hypertension in pregnant women with teletransmitted home blood pressure. Hypertens Preg. 2008;27(3):305–313. doi: 10.1080/10641950802000950. PubMed DOI

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041. doi: 10.1097/HJH.0000000000001940. PubMed DOI

Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia-pathophysiology and clinical presentations: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76(14):1690–1702. doi: 10.1016/j.jacc.2020.08.014. PubMed DOI

Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Preg Hypertens. 2018;13:291–310. doi: 10.1016/j.preghy.2018.05.004. PubMed DOI

Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation. 2014;129(11):1254–1261. doi: 10.1161/CIRCULATIONAHA.113.003904. PubMed DOI

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13–22. doi: 10.1056/NEJMoa1414838. PubMed DOI

Verlohren S, Brennecke SP, Galindo A, Karumanchi SA, Mirkovic LB, Schlembach D, et al. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Preg Hypertens. 2022;27:42–50. doi: 10.1016/j.preghy.2021.12.003. PubMed DOI

Huhn EA, Kreienbühl A, Hoffmann I, Schoetzau A, Lange S, de Tejada BM, et al. Diagnostic accuracy of different soluble fms-like tyrosine kinase 1 and placental growth factor cut-off values in the assessment of preterm and term preeclampsia: a gestational age matched case-control study. Front Med (Lausanne). 2018;5:325. doi: 10.3389/fmed.2018.00325. PubMed DOI PMC

Cerdeira AS, O'Sullivan J, Ohuma EO, James T, Papageorghiou AT, Knight M, et al. Performance of soluble fms-like tyrosine kinase-1-to-placental growth factor ratio of ≥85 for ruling in preeclampsia within 4 weeks. Am J Obstet Gynecol. 2021;224(3):322–323. doi: 10.1016/j.ajog.2020.11.007. PubMed DOI

Gaccioli F, Sovio U, Gong S, Cook E, Charnock-Jones DS, Smith GCS. Increased placental sFLT1 (Soluble fms-Like Tyrosine Kinase Receptor-1) drives the antiangiogenic profile of maternal serum preceding preeclampsia but not fetal growth restriction. Hypertension. 2023;80(2):325–334. doi: 10.1161/HYPERTENSIONAHA.122.19482. PubMed DOI PMC

Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci. 2007;44(1):1–85. doi: 10.1080/10408360600931831. PubMed DOI

Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco MC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622. doi: 10.1056/NEJMoa1704559. PubMed DOI

Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, et al. First international consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens. 2019;37(2):229–252. doi: 10.1097/HJH.0000000000002019. PubMed DOI

Lenders JW. Pheochromocytoma and pregnancy: a deceptive connection. Eur J Endocrinol. 2012;166(2):143–150. doi: 10.1530/EJE-11-0528. PubMed DOI

Morton A. Primary aldosteronism and pregnancy. Pregnancy Hypertens. 2015;5(4):259–262. doi: 10.1016/j.preghy.2015.08.003. PubMed DOI

Landau E, Amar L. Primary aldosteronism and pregnancy. Ann Endocrinol (Paris) 2016;77(2):148–160. doi: 10.1016/j.ando.2016.04.009. PubMed DOI

Almasi-Hashiani A, Omani-Samani R, Mohammadi M, Amini P, Navid B, Alizadeh A, et al. Assisted reproductive technology and the risk of preeclampsia: an updated systematic review and meta-analysis. BMC Preg Childb. 2019;19(1):149. doi: 10.1186/s12884-019-2291-x. PubMed DOI PMC

Chih HJ, Elias FTS, Gaudet L, Velez MP. Assisted reproductive technology and hypertensive disorders of pregnancy: systematic review and meta-analyses. BMC Preg Childb. 2021;21(1):449. doi: 10.1186/s12884-021-03938-8. PubMed DOI PMC

Sindre HP, Westvik-Johari K, Spangmose AL, Pinborg A, Romundstad LB, Bergh C, et al. Risk of hypertensive disorders in pregnancy after fresh and frozen embryo transfer in assisted reproduction: a population-based cohort study with within-sibship analysis. Hypertension. 2023;80(2):e6–e16. PubMed

Hofmeyr GJ, Lawrie TA, Atallah ÁN, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2018;10(10):Cd001059. PubMed PMC

Woo J, Giurgescu C, Wagner CL. Evidence of an association between vitamin D deficiency and preterm birth and preeclampsia: a critical review. J Midwif Womens Health. 2019;64(5):613–629. doi: 10.1111/jmwh.13014. PubMed DOI

Fogacci S, Fogacci F, Banach M, Michos ED, Hernandez AV, Lip GYH, et al. Vitamin D supplementation and incident preeclampsia: a systematic review and meta-analysis of randomized clinical trials. Clin Nutr. 2020;39(6):1742–1752. doi: 10.1016/j.clnu.2019.08.015. PubMed DOI

Rossi AC, Mullin PM. Prevention of pre-eclampsia with low-dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2011;158(1):9–16. doi: 10.1016/j.ejogrb.2011.04.010. PubMed DOI

Villar J, Purwar M, Merialdi M, Zavaleta N, Thi Nhu Ngoc N, Anthony J, et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG. 2009;116(6):780–788. doi: 10.1111/j.1471-0528.2009.02158.x. PubMed DOI

Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet. 2006;367(9517):1145–1154. doi: 10.1016/S0140-6736(06)68433-X. PubMed DOI

Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647–649. doi: 10.1016/S0140-6736(82)92202-4. PubMed DOI

Redman CW, Beilin LJ, Bonnar J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br J Obstet Gynaecol. 1977;84(6):419–426. doi: 10.1111/j.1471-0528.1977.tb12616.x. PubMed DOI

Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;2014(2):Cd002252. PubMed

Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007;207(1):Cd002252. PubMed

Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;10(10):Cd002252. PubMed PMC

Bone JN, Sandhu A, Abalos ED, Khalil A, Singer J, Prasad S, et al. Oral antihypertensives for nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential analyses. Hypertension. 2022;79(3):614–628. doi: 10.1161/HYPERTENSIONAHA.121.18415. PubMed DOI PMC

Webster K, Fishburn S, Maresh M, Findlay SC, Chappell LC. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ. 2019;366:l5119. doi: 10.1136/bmj.l5119. PubMed DOI

Physical activity and exercise during pregnancy and the postpartum period: ACOG Committee Opinion Summary, Number 804. Obstet Gynecol. 2020;135(4):991–3. PubMed

Di Mascio D, Magro-Malosso ER, Saccone G, Marhefka GD, Berghella V. Exercise during pregnancy in normal-weight women and risk of preterm birth: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2016;215(5):561–571. doi: 10.1016/j.ajog.2016.06.014. PubMed DOI

Barakat R, Pelaez M, Cordero Y, Perales M, Lopez C, Coteron J, et al. Exercise during pregnancy protects against hypertension and macrosomia: randomized clinical trial. Am J Obstet Gynecol. 2016;214(5):649.e1–8. doi: 10.1016/j.ajog.2015.11.039. PubMed DOI

Santos S, Voerman E, Amiano P, Barros H, Beilin LJ, Bergström A, et al. Impact of maternal body mass index and gestational weight gain on pregnancy complications: an individual participant data meta-analysis of European, North American and Australian cohorts. BJOG. 2019;126(8):984–995. PubMed PMC

Martínez-Vizcaíno V, Sanabria-Martínez G, Fernández-Rodríguez R, Cavero-Redondo I, Pascual-Morena C, Álvarez-Bueno C, et al. Exercise during pregnancy for preventing gestational diabetes mellitus and hypertensive disorders: an umbrella review of randomised controlled trials and an updated meta-analysis. BJOG. 2023;130(3):264–275. doi: 10.1111/1471-0528.17304. PubMed DOI PMC

Dodd JM, Turnbull D, McPhee AJ, Deussen AR, Grivell RM, Yelland LN, et al. Antenatal lifestyle advice for women who are overweight or obese: LIMIT randomised trial. BMJ. 2014;348:g1285. doi: 10.1136/bmj.g1285. PubMed DOI PMC

Maxwell C, Gaudet L, Cassir G, Nowik C, McLeod NL, Jacob C, et al. Guideline no. 391-pregnancy and maternal obesity part 1: pre-conception and prenatal care. J Obstet Gynaecol Can. 2019;41(11):1623–1640. doi: 10.1016/j.jogc.2019.03.026. PubMed DOI

Maxwell C, Gaudet L, Cassir G, Nowik C, McLeod NL, Jacob C, et al. Guideline no. 392-pregnancy and maternal obesity part 2: team planning for delivery and postpartum care. J Obstet Gynaecol Can. 2019;41(11):1660–1675. doi: 10.1016/j.jogc.2019.03.027. PubMed DOI

Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955–960. doi: 10.1136/bmj.327.7421.955. PubMed DOI PMC

Antza C, Dimou C, Doundoulakis I, Akrivos E, Stabouli S, Haidich AB, et al. The flipside of hydralazine in pregnancy: a systematic review and meta-analysis. Preg Hypertens. 2020;19:177–186. doi: 10.1016/j.preghy.2020.01.011. PubMed DOI

Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(9):1906–1916. doi: 10.1111/bcp.13649. PubMed DOI PMC

Cífková R, Johnson MR, Kahan T, Brguljan J, Williams B, Coca A, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):384–393. doi: 10.1093/ehjcvp/pvz082. PubMed DOI

Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877–1890. doi: 10.1016/S0140-6736(02)08778-0. PubMed DOI

Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;2010(11):Cd000025. PubMed PMC

Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407–417. doi: 10.1056/NEJMoa1404595. PubMed DOI

August P. Lowering diastolic blood pressure in non-proteinuric hypertension in pregnancy is not harmful to the fetus and is associated with reduced frequency of severe maternal hypertension. Evid Based Med. 2015;20(4):141. doi: 10.1136/ebmed-2015-110203. PubMed DOI

Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for mild chronic hypertension during pregnancy. N Engl J Med. 2022;386(19):1781–1792. doi: 10.1056/NEJMoa2201295. PubMed DOI PMC

Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374(9694):979–988. doi: 10.1016/S0140-6736(09)60736-4. PubMed DOI

Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326(7394):845. doi: 10.1136/bmj.326.7394.845. PubMed DOI PMC

Søndergaard MM, Hlatky MA, Stefanick ML, Vittinghoff E, Nah G, Allison M, et al. Association of adverse pregnancy outcomes with risk of atherosclerotic cardiovascular disease in postmenopausal women. JAMA Cardiol. 2020;5(12):1390–1398. doi: 10.1001/jamacardio.2020.4097. PubMed DOI PMC

Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2):e003497. PubMed

Countouris ME, Villanueva FS, Berlacher KL, Cavalcante JL, Parks WT, Catov JM. Association of hypertensive disorders of pregnancy with left ventricular remodeling later in life. J Am Coll Cardiol. 2021;77(8):1057–1068. doi: 10.1016/j.jacc.2020.12.051. PubMed DOI PMC

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350. doi: 10.1016/j.jacc.2018.11.003. PubMed DOI

Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015;36(18):1090–1097. doi: 10.1093/eurheartj/ehv009. PubMed DOI PMC

Gammill HS, Chettier R, Brewer A, Roberts JM, Shree R, Tsigas E, et al. Cardiomyopathy and preeclampsia. Circulation. 2018;138(21):2359–2366. doi: 10.1161/CIRCULATIONAHA.117.031527. PubMed DOI

Paradisi G, Biaggi A, Savone R, Ianniello F, Tomei C, Caforio L, et al. Cardiovascular risk factors in healthy women with previous gestational hypertension. J Clin Endocrinol Metab. 2006;91(4):1233–1238. doi: 10.1210/jc.2005-1337. PubMed DOI

Schliep KC, McLean H, Yan B, Qeadan F, Theilen LH, de Havenon A, et al. Association between hypertensive disorders of pregnancy and dementia: a systematic review and meta-analysis. Hypertension. 2023;80(2):257–267. doi: 10.1161/HYPERTENSIONAHA.122.19399. PubMed DOI PMC

Escudero C, Kupka E, Ibañez B, Sandoval H, Troncoso F, Wikström AK, et al. Brain vascular dysfunction in mothers and their children exposed to preeclampsia. Hypertension. 2023;80(2):242–256. doi: 10.1161/HYPERTENSIONAHA.122.19408. PubMed DOI

Heida KY, Bots ML, de Groot CJ, van Dunné FM, Hammoud NM, Hoek A, et al. Cardiovascular risk management after reproductive and pregnancy-related disorders: a Dutch multidisciplinary evidence-based guideline. Eur J Prev Cardiol. 2016;23(17):1863–1879. doi: 10.1177/2047487316659573. PubMed DOI

Kitt J, Frost A, Mollison J, Tucker KL, Suriano K, Kenworthy Y, et al. Postpartum blood pressure self-management following hypertensive pregnancy: protocol of the Physician Optimised Post-partum Hypertension Treatment (POP-HT) trial. BMJ Open. 2022;12(2):e051180. doi: 10.1136/bmjopen-2021-051180. PubMed DOI PMC

Spaan J, Peeters L, Spaanderman M, Brown M. Cardiovascular risk management after a hypertensive disorder of pregnancy. Hypertension. 2012;60(6):1368–1373. doi: 10.1161/HYPERTENSIONAHA.112.198812. PubMed DOI

Arnott C, Patel S, Hyett J, Jennings G, Woodward M, Celermajer DS. Women and cardiovascular disease: pregnancy, the forgotten risk factor. Heart Lung Circ. 2020;29(5):662–667. doi: 10.1016/j.hlc.2019.09.011. PubMed DOI

Yang H, Kuhn C, Kolben T, Ma Z, Lin P, Mahner S, et al. Early life oxidative stress and long-lasting cardiovascular effects on offspring conceived by assisted reproductive technologies: a review. Int J Mol Sci. 2020;21(15):5175. doi: 10.3390/ijms21155175. PubMed DOI PMC

Thomopoulos C, Salamalekis G, Kintis K, Andrianopoulou I, Michalopoulou H, Skalis G, et al. Risk of hypertensive disorders in pregnancy following assisted reproductive technology: overview and meta-analysis. J Clin Hypertens (Greenwich) 2017;19(2):173–183. doi: 10.1111/jch.12945. PubMed DOI PMC

Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24–43. doi: 10.1161/HYPERTENSIONAHA.117.10803. PubMed DOI

Scherrer U, Rexhaj E, Allemann Y, Sartori C, Rimoldi SF. Cardiovascular dysfunction in children conceived by assisted reproductive technologies. Eur Heart J. 2015;36(25):1583–1589. doi: 10.1093/eurheartj/ehv145. PubMed DOI

Meister TA, Rimoldi SF, Soria R, von Arx R, Messerli FH, Sartori C, et al. Association of assisted reproductive technologies with arterial hypertension during adolescence. J Am Coll Cardiol. 2018;72(11):1267–1274. doi: 10.1016/j.jacc.2018.06.060. PubMed DOI

Cui L, Zhao M, Zhang Z, Zhou W, Lv J, Hu J, et al. Assessment of cardiovascular health of children ages 6 to 10 years conceived by assisted reproductive technology. JAMA Netw Open. 2021;4(11):e2132602. doi: 10.1001/jamanetworkopen.2021.32602. PubMed DOI PMC